Figure 3 | Scientific Reports

Figure 3

From: Identification of two early blood biomarkers ACHE and CLEC12A for improved risk stratification of critically ill COVID-19 patients

Figure 3The alternative text for this image may have been generated using AI.

Identification of the putative biomarkers CLEC12A and ACHE. (a) Venn diagram comparing DEGs of COVID-19 patients at day 0 and day 7. 24 out of 359 DEGs were identified at both time points. Blue circles indicate genes with high expression in survivors and red triangles represent genes with high expression in non-survivors. (b) Boxplot showing the significantly decreased mean expression of CLEC12A in the blood transcriptome of non-survivors (red) separately for day 0 and day 7. (c) Boxplot showing the significantly increased mean expression of ACHE in the blood transcriptome of survivors (blue) separately for day 0 and day 7. Two-sided Wilcoxon test with n = 24 (survivor n = 12, non-survivor n = 12) was performed for both time points. Additionally, unequal variance t-tests were performed for both time points (pACHE,day0 = 0.0019, pACHE,day7 = 0.0063, pCLEC12A,day0 = 0.0002, pCLEC12A,day7 = 0.0001). (d) ROC curves for predicting the outcome of COVID-19 patients using CLEC12A at day 0, day 7, and for both time points combined. (e) ROC curves for predicting the outcome of COVID-19 patients using ACHE at day 0, day 7, and for both time points combined.

Back to article page